Latest Breaking News On - Homozygous familial hypercholesterolaemia - Page 11 : comparemela.com
Amryt Pharma PLC (AIM:AMYT) | RNS | Amryt Submits a New Drug Application to the US Food and Drug Administration for Oleogel-S10* (Filsuv
proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.
Exercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
Exercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
DUBLIN, Ireland, and Boston MA, March 11, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces that subscription rights relating to warrants to acquire 283,389 Ordinary Shares (the “Warrants”) have been exercised. In order to satisfy the exercise of the Warrants, the Company on 11 March 2021 issued 283,389 ordinary shares of £0.06 each (“Ordinary Shares”) from treasury.
The Warrants were issued in connection with the listing of the Company on the AIM Market of the London Stock Exchange in 2016. Each warrant entitles the warrant holder to exercise subscription rights to subscribe for Ordinary Shares at a subscription price of £1.44 per Ordinary Share.
Grant of Options and Notification of Transactions by Persons Discharging Managerial Responsibilities
DUBLIN, Ireland, and Boston MA, March 8, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel treatments for rare diseases, today announces that the Remuneration Committee has approved the grant of 3,431,350 share options (
Options ) to subscribe for ordinary shares in the Company (
Shares ) under the Employee Share Option Plan 2019 (the
Plan ) to Joe Wiley, CEO, and Rory Nealon, CFO, details of which are set out in the table below.
The Options have an exercise price of US$2.804 per Share ($14.02 per ADS equivalent) (
Amryt Supports Global Rare Disease Day 2021
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Share:
Amryt and Medison Pharma Sign Multi-Regional Distribution Agreements in Canada and Israel
DUBLIN, Ireland, and Boston MA, February 4, 2021, Amryt (NASDAQ:AMYT, AIM: AMYT)), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases, today announces the signing of multi-regional distribution agreements with Medison Pharma ( Medison ) to distribute Juxtapid® (lomitapide) in Canada and Lojuxta® (lomitapide) and Myalept® (metreleptin) in Israel.
Dr Joe Wiley, CEO of Amryt Pharma, commented today:
Today s announcement is another positive development as we continue to grow our commercial assets in existing and new territories and we further progress towards our goal of becoming a global leader in rare and orphan diseases. We are excited to be working with Medison to leverage their expertise and presence in these territories.
vimarsana © 2020. All Rights Reserved.